INTRODUCTION: New technologies for therapeutic cooling have become available. The objective of our study was to investigate the safety of nasopharyngeal cooling with the RhinoChill(®) device in stroke patients, focusing on systemic and neurovital parameters. METHODS: In this prospective observational study, consecutive patients with severe ischemic or hemorrhagic stroke who underwent intracranial pressure (ICP) and brain temperature monitoring have been enrolled. Ten patients who were treated with the RhinoChill(®) device were analyzed. Brain and bladder temperature and systemic and neurovital parameters were monitored continuously. Additional evaluations of safety included bleeding complications and otolaryngological examinations. RESULTS: Baseline brain temperature of 36.7 °C (SD 0.9) decreased by an average of 1.21 °C (SD 0.46) within 1 h, the effect of brain temperature decrease ranged from a maximum of 2 °C (patients 3 and 7) to a minimum of 0.6 °C (patient 4). Within the first several minutes after initiating RhinoChill(®) treatment, 3 of 10 patients experienced an increase in systolic arterial pressure by 30, 30, and 53 mmHg, respectively. Heart rate rose as well (mean 3 bpm, SD 2.9). ICP and oxygen saturation were unaffected by the treatment. We observed 1 bleeding complication in the control CT scan of patient 10. Rhinoscopical findings 3 days after nasopharyngeal cooling and at the follow-up (>6 months) and a 16-item smell test were normal. CONCLUSION: The RhinoChill(®) system cools the brain efficiently. However, steep increases in blood pressure raise serious concerns regarding the safety of its use in stroke patients.
INTRODUCTION: New technologies for therapeutic cooling have become available. The objective of our study was to investigate the safety of nasopharyngeal cooling with the RhinoChill(®) device in strokepatients, focusing on systemic and neurovital parameters. METHODS: In this prospective observational study, consecutive patients with severe ischemic or hemorrhagic stroke who underwent intracranial pressure (ICP) and brain temperature monitoring have been enrolled. Ten patients who were treated with the RhinoChill(®) device were analyzed. Brain and bladder temperature and systemic and neurovital parameters were monitored continuously. Additional evaluations of safety included bleeding complications and otolaryngological examinations. RESULTS: Baseline brain temperature of 36.7 °C (SD 0.9) decreased by an average of 1.21 °C (SD 0.46) within 1 h, the effect of brain temperature decrease ranged from a maximum of 2 °C (patients 3 and 7) to a minimum of 0.6 °C (patient 4). Within the first several minutes after initiating RhinoChill(®) treatment, 3 of 10 patients experienced an increase in systolic arterial pressure by 30, 30, and 53 mmHg, respectively. Heart rate rose as well (mean 3 bpm, SD 2.9). ICP and oxygen saturation were unaffected by the treatment. We observed 1 bleeding complication in the control CT scan of patient 10. Rhinoscopical findings 3 days after nasopharyngeal cooling and at the follow-up (>6 months) and a 16-item smell test were normal. CONCLUSION: The RhinoChill(®) system cools the brain efficiently. However, steep increases in blood pressure raise serious concerns regarding the safety of its use in strokepatients.
Authors: Maaret Castrén; Per Nordberg; Leif Svensson; Fabio Taccone; Jean-Louise Vincent; Didier Desruelles; Frank Eichwede; Pierre Mols; Tilmann Schwab; Michel Vergnion; Christian Storm; Antonio Pesenti; Jan Pachl; Fabien Guérisse; Thomas Elste; Markus Roessler; Harald Fritz; Pieterjan Durnez; Hans-Jörg Busch; Becky Inderbitzen; Denise Barbut Journal: Circulation Date: 2010-08-02 Impact factor: 29.690
Authors: Thorsten Steiner; Markku Kaste; Markku Katse; Michael Forsting; David Mendelow; Hubert Kwiecinski; Istvan Szikora; Seppo Juvela; Andrzej Marchel; René Chapot; Christophe Cognard; Andreas Unterberg; Werner Hacke Journal: Cerebrovasc Dis Date: 2006-07-28 Impact factor: 2.762
Authors: L P Kammersgaard; H S Jørgensen; J A Rungby; J Reith; H Nakayama; U J Weber; J Houth; T S Olsen Journal: Stroke Date: 2002-07 Impact factor: 7.914
Authors: Sven Poli; Jan Purrucker; Miriam Priglinger; Matthias Ebner; Marek Sykora; Jennifer Diedler; Cem Bulut; Erik Popp; André Rupp; Christian Hametner Journal: Crit Care Date: 2014-10-27 Impact factor: 9.097
Authors: Turner S Baker; Christopher P Kellner; Frederick Colbourne; Fred Rincon; Rainer Kollmar; Neeraj Badjatia; Neha Dangayach; J Mocco; Magdy H Selim; Patrick Lyden; Kees Polderman; Stephan Mayer Journal: Front Neurol Date: 2022-08-17 Impact factor: 4.086